1

2 Cross-sectional cycle threshold values reflect epidemic dynamics of COVID-19 in Madagascar

3

4 Authors and affiliations:

- 5 Soa Fy Andriamandimby, Virology Unit, Institut Pasteur de Madagascar*
- Cara E. Brook, Department of Ecology and Evolution, University of Chicago* 6
- 7 Norosoa Razanazatovo, Virology Unit, Institut Pasteur de Madagascar
- 8 Jean-Marius Rakotondramanga, Epidemiology and Clinical Research Unit, Institut Pasteur de
- 9 Madagascar
- 10 Fidisoa Rasambainarivo, Department of Ecology and Evolutionary Biology, Princeton
- 11 University
- Vaomalala Raharimanga, Epidemiology and Clinical Research Unit, Institut Pasteur de 12 13 Madagascar
- Iony Manitra Razanajatovo, Virology Unit, Institut Pasteur de Madagascar 14
- 15 Reziky Mangahasimbola, Epidemiology and Clinical Research Unit, Institut Pasteur de 16 Madagascar
- 17 Richter Razafindratsimandresy, Virology Unit, Institut Pasteur de Madagascar
- 18 Santatra Randrianarisoa, Department of Veterinary Sciences and Medicine, University of
- 19 Antananarivo
- 20 Barivola Bernardson, Epidemiology and Clinical Research Unit, Institut Pasteur de Madagascar
- 21 Joelinotahiana Hasina Rabarison, Virology Unit, Institut Pasteur de Madagascar
- Mirella Randrianarisoa, Epidemiology and Clinical Research Unit, Institut Pasteur de Madagascar 22
- Frédérick Stanley Nasolo, Virology Unit, Institut Pasteur de Madagascar 23
- 24 Roger Mario Rabetombosoa, Epidemiology and Clinical Research Unit, Institut Pasteur de 25 Madagascar
- Rindra Randremanana[#], Epidemiology and Clinical Research Unit, Institut Pasteur de 26
- 27 Madagascar
- Jean-Michel Héraud^{#†}, Virology Unit, Institut Pasteur of Dakar 28
- 29 Philippe Dussart[#], Virology Unit, Institut Pasteur de Madagascar
- 30

31 Contact info for corresponding author:

- Soa Fy Andriamandimby, Virology Unit, Institut Pasteur de Madagascar, soafy@pasteur.mg 32
- 33 *Lead authors contributed equally.
- [#]These senior authors contributed equally to this work. 34
- 35 [†]Present address: Virology Department, Institut Pasteur de Dakar.
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

48 Abstract:

- 49 As the national reference laboratory for febrile illness in Madagascar, we processed samples
- 50 from the first epidemic wave of COVID-19, between March and September 2020. We fit
- 51 generalized additive models to cycle threshold (C_t) value data from our RT-qPCR platform,
- $\label{eq:constrating} 52 \qquad \text{demonstrating a peak in high viral load, low-C_t value infections temporally coincident with peak}$
- 53 epidemic growth rates estimated in real time from publicly-reported incidence data and
- retrospectively from our own laboratory testing data across three administrative regions. We
- additionally demonstrate a statistically significant effect of duration of time since infection onset
- 56 on C_t value, suggesting that C_t value can be used as a biomarker of the stage at which an
- 57 individual is sampled in the course of an infection trajectory. As an extension, the population-
- 58 level C_t distribution at a given timepoint can be used to estimate population-level
- 59 epidemiological dynamics. We illustrate this concept by adopting a recently-developed, nested
- 60 modeling approach, embedding a within-host viral kinetics model within a population-level
- 61 Susceptible-Exposed-Infectious-Recovered (SEIR) framework, to mechanistically estimate
- We find that C_t-derived epidemic growth estimates slightly precede those derived from incidence
- 64 data across the first epidemic wave, suggesting delays in surveillance and case reporting. Our
- findings indicate that public reporting of C_t values could offer an important resource for
- 66 epidemiological inference in low surveillance settings, enabling forecasts of impending
- 67 incidence peaks in regions with limited case reporting.

Key Words: COVID-19, LMIC, Madagascar, Africa, cycle threshold value, cross-sectional data

93

94 Introduction.

95 Madagascar reported its first case of coronavirus disease 2019 (COVID-19) on 19 March 96 2020, in part with a government-sponsored surveillance platform testing all incoming 97 international travelers [1]. Subsequent to this introduction, the first wave of the COVID-19 98 epidemic was geographically staggered, with early cases in May 2020 largely concentrated in the 99 eastern city of Toamasina, part of the Atsinanana administrative region, followed by a more 100 severe outbreak which peaked in July 2020 in the capital city of Antananarivo, part of the 101 Analamanga administrative region. Test positive rates exceeded 50% at the epidemic peak for 102 both regions and at the national level, indicating widespread underreporting [2], a common 103 feature of COVID-19, for which some 20-40% of infections are thought to be entirely 104 asymptomatic [3–6]. Early reporting on the first epidemic wave in Madagascar indicated an 105 extremely high (56.6%) proportion of asymptomatic cases, based on targeted surveillance of 106 symptomatic patients and their contacts [1].

107 Madagascar closed its borders to international air travel on 20 March 2020 and, 108 subsequent to identification of the first case, implemented several non-pharmaceutical 109 interventions aimed at curbing epidemic spread, including non-essential business closures, 110 curfews, stay-at-home orders, and mandates for social distancing. These restrictions were relaxed 111 after the first epidemic subsided in September 2020 but have since been re-implemented in the 112 face of a second epidemic wave. In other regions of the globe, widespread efforts to estimate the 113 effective reproduction number, R_t , for COVID-19 at national, regional, and local levels [7] have been used to inform public health interventions and retrospectively assess their effectiveness [8]: 114 115 disease transmission rates are increasing at $R_t > 1$ and decreasing at $R_t < 1$. Estimation of R_t , or 116 its related counterpart, r, the epidemic growth rate [9,10], from available case count data is 117 challenged by limitations or variability in surveillance, uncertainty surrounding the shape of 118 disease parameter distributions, and delays in reporting [8]. Despite the enormity of these 119 challenges in the limited surveillance settings common to many lower- and middle-income 120 countries (LMICs), real-time estimation of R_t from COVID-19 case-counts has been attempted 121 for most regions of the globe [7] and has been implemented locally in Madagascar [11].

122 Recent methodological advances have introduced a new resource to the epidemiological 123 toolkit by which to conduct real time estimation of epidemic trajectories [12], one that leverages 124 the often-discarded cycle threshold, or C_t , value, that is returned as an-inverse log-10 measure of 125 viral load from all RT-qPCR-based platforms [13]. After observing that SARS-CoV-2 viral loads—and, as a consequence RT-qPCR Ct values—demonstrate a predictable trajectory 126 127 following the onset of infection [14–16], Hay et al. 2020 showed that the Ct value can be used as a biomarker of time since infection and, consequently, be leveraged to back-calculate infection 128 129 incidence, in a manner analogous to previous work leveraging serological titer information in 130 other systems [17–19]. Probabilistically, a randomly-selected infection is more likely to be early 131 in its infection trajectory when identified during a growing epidemic and later in its trajectory in 132 a declining epidemic [20,21], and as a consequence, the population-level distribution of C_t values 133 for any viral infection is expected to shift across the duration of an epidemic. Indeed, low-Ct-134 high-viral-load infections have been observed to coincide with growing COVID-19 epidemics 135 and high-Ct-low-viral-load infections with declining epidemics in several settings [15,22,23]. 136 Exploiting this phenomenon, Hay et al. 2020 developed a method that embeds a within-host, 137 viral kinetics model in a population-level disease transmission model to derive epidemic 138 trajectories from cross-sectional C_t samples. Because this method depends on quantitative

information captured in the biological sample itself, rather than the relationship between case
 count and reporting date, Ct value estimation more accurately predicts true epidemic trajectories
 than traditional incidence estimation in settings with uneven surveillance [12].

142 During the early phase of the COVID-19 epidemic in Madagascar, the Virology Unit 143 laboratory (National Influenza Centre) at the Institut Pasteur of Madagascar (IPM) processed the 144 majority of all SARS-CoV-2 testing samples derived from 114 districts across 6 major provinces 145 in the country. Consistent with findings reported elsewhere [15,22,23], we observed a 146 population-level decline in Ct values derived from RT-qPCR-testing in our laboratory, coincident 147 with the epidemic peak across the first wave of COVID-19 in Madagascar. We here adopt the 148 methods presented by Hay et al. 2020 to estimate COVID-19 epidemic growth rates at the 149 national level (2018 population ~26 million [24]) and in two major administrative regions of 150 Madagascar: Atsinanana (east coast of Madagascar; 2018 population ~1.5 million [24]) and 151 Analamanga (including Antananarivo, capital city; 2018 population ~3.6 million [24]). These 152 two regions comprised the geographic epicenter of the first COVID-19 wave in Madagascar; 153 data from other regions were too sparse for epidemiological inference. We evaluate the

robustness of this C_t -based method in comparison with epidemic growth rates derived from more

traditional case-count methods applied to the same regions.

156 Materials and Methods.

157 158 *IPM SARS-CoV-2 C_t Data.*

159 Methods for collection, transport, and processing of SARS-CoV-2 testing samples at IPM have been previously described [1]. Briefly, nasopharyngeal and oropharyngeal swabs were 160 161 collected at local administrative hospitals in viral transport medium and transported at 4°C to our 162 laboratory for testing. Between 18 March and 30 September 2020, we conducted 34,563 RT-163 qPCR tests targeting the E, N, Orf1a/b, or S gene of SARS-CoV-2. These tests were carried out 164 across 20,326 discrete samples (many of which were tested across multiple platforms targeting multiple genes), and 17,499 discrete patients, a subset of whom were tested at multiple 165 timepoints. The majority of tests were conducted on individuals who independently sought 166 testing, due to concerns about exposure or symptom presentation, though a subset of samples 167 168 were derived from efforts to trace and test contacts of positive travelers in the early stages of the 169 pandemic [1]. The reason each patient sought testing was not recorded in the original data.

Due to a dearth of available reagents in the early stages of the epidemic, our lab used
seven different WHO-recommended kits and corresponding protocols [25] to assay infection in
these samples [1]: Charity Berlin [26], Hong Kong University [27], Da An gene (Da An Gene
Co., Ltd. Sun Yatsen University, Guangzhou, China), LightMix® SarbeCoV E-gene plus EAV
control (TIB Biolmol, Berlin, Germany), SarbeCoV TibMolBiol (TIB Biolmol, Berlin,

Germany), TaqPath[™] COVID- 19 Combo kit (Life Technologies Ltd, Paisley, UK), and
 GeneXpert (Cepheid, Sunnyvale, CA, USA).

177Some 9,493 of those tests, corresponding to 5,310 individuals, were RT-qPCR positive178for SARS-CoV-2 infection based on the cut-off positive value for the test in question (Charity179Berlin: <= 38; Hong Kong: <=40; Da An: <= 40; LightMix SarbeCoV/SarbeCoV TibMolBiol <=</td>18038; TaqPath <= 37 for 2 of 3 targets; GeneXpert = <= 40). All analyses presented in this paper</td>181are derived from these positive test results, as Ct-values were not reliably recorded following182negative results. We further subset our data as appropriate for each analysis of interest.

185

186 *Estimating growth rates from IPM case data.*

187 We first sought to obtain an estimate of new daily cases reported from our laboratory to 188 the Malagasy government between 18 March and 30 September 2020. To this end, we reduced our dataset to include only sampling from the first reported positive test date for each unique 189 190 patient; we assumed that reinfection was unlikely within the short duration of our study and that 191 any subsequent positive tests were reflective of longer-duration infections in repeatedly sampled 192 individuals. A patient was considered "positive" for SARS-CoV-2 infection if any test for any SARS-CoV-2 target was positive, and the results of the other samples were not inconsistent with 193 194 this finding. We then summed cases by date at the national level and for two administrative 195 regions (Atsinanana and Analamanga) that reported the majority of total cases across the study 196 period overall. In total, 5,276 cases were reported from our laboratory across the study period at 197 the national level, 3,505 in Analamanga region and 758 in Atsinanana. Daily cases for the two 198 target regions and for the nation at large are summarized in Fig. 1.

199



200 201

Fig. 1. Epidemic growth rate estimates from case count data across the first wave of COVID-19 in

Madagascar. (A.) Map of Madagascar, colored by regions of case count tabulation, showing the Atsinanana region (orange), the Analamanga region (green), and the National region (blue); note that data analyzed at the National level includes data from both Atsinanana and Analamanga regions, as well as the rest of Madagascar. (B.) Time series of new case incidence (lefthand y-axis) across the first wave of COVID-19 in Madagascar (18 March – 30 September 2020), across three focal regions. Darker shading shows data derived from the IPM RT-qPCR platform, while lighter shading depicts data nationally reported and consolidated on [11]. Righthand y-axis shows

corresponding epidemic growth rate computed from case count data in EpiNow2 [28], with darker line

corresponding to computation from IPM data and lighter line to computation from publicly reported data;
 background shading around each line depicts the corresponding 50% quantile by EpiNow2 [28].

212 We applied the opensource R-package EpiNow2 [28] to the daily incidence data to 213 estimate the epidemic growth rate for COVID-19 across the study period. EpiNow2 builds on 214 previous R_t estimation packages [29], using a non-stationary Gaussian process model to estimate 215 the instantaneous time-varying reproduction number, R_t , and the corresponding time-varying 216 epidemic growth rate, r, while incorporating uncertainty in the generation interval. Following 217 best recommended practices [8], we modeled the SARS-CoV-2 incubation period as a log-218 normal distribution with a mean of 1.621 days (sd=0.064) and a standard deviation of 0.418 days 219 (sd=0.061) [30] and the generation time interval as a gamma distribution with a mean of 3.635 220 (sd=0.71) and a standard deviation of 3.075 (0.77) [31]. Since the IPM testing data reported the 221 actual date of sample collection, no reporting delay was incorporated in our growth rate 222 estimation.

223

224 Epidemic trajectories from publicly reported data.

225 To compare our laboratory-derived epidemic growth estimates with those undertaken in 226 real time in Madagascar, we collaborated with colleagues who recorded data on the number of 227 new PCR-confirmed cases reported daily on national television by the Ministry of Health of the 228 Government of Madagascar across the duration of the first epidemic wave. From these daily case 229 estimates, we used the EpiNow2 package [28] to again estimate the epidemic growth rate across 230 the same study period, assuming the same incubation period and general time interval referenced 231 above [30,31]. For these estimates, we followed methods outlined in [32], to additionally model 232 a reporting delay from a log-normal distribution fit to 100 subsamples with 1000 bootstraps from 233 a publicly available linelist that collates data globally for COVID-19 cases for which both 234 infection onset and notification dates are available [33].

235

236 *Standardizing* C_t values across tests and targets.

237 In our next series of analyses, we leveraged information captured in the individual C_t 238 value returned from each positive test. To control for extensive variation in qPCR test and target 239 (each of which reported varying thresholds for positivity), we carried out *in vitro* experiments 240 using SARS-CoV-2 isolates from infected patients reporting similar Ct values on the TaqPath 241 platform at the time of sampling. Briefly, three SARS-CoV-2 isolates (designated hCoV-242 19/Madagascar/IPM-00754/2021, hCoV-19/Madagascar/IPM-01263/2021 and hCoV-243 19/Madagascar/IPM-01315/2021) were obtained and cultured in Vero cells as previously 244 described [34]. Upon infection with SARS-CoV-2, the culture medium was replaced by infection 245 medium containing DMEM, 5 % FBS, antibiotics, 2.5 µg/ml Amphotericin B (Gibco) and 16 246 µg/ml TPCK-trypsin (Gibco). Virus-containing supernatants, as determined by the presence of 247 cytopathic effect (CPE), were harvested 7 days after infection by centrifugation at 1500 r.p.m. 248 for 10 min. RNA was subsequently extracted from supernatant and subjected to serial dilutions 249 and subsequent testing on six of the seven RT-qPCR platforms used in our population-level 250 dataset (LightMix SarbeCoV and SarbeCoV TibMolBiol were considered equivalent and tested 251 only using the current version of the kit: SarbeCoV TibMolBiol). We fit linear mixed effect 252 regression models in the lme4 [35] package in R to the resulting C_t curves returned from each 253 testing platform across the dilution series and used the fitted slope and y-intercept of each 254 regression equation to reproject all Ct values in our dataset to correspond to results returned from

255 the TaqPath N gene test. We report, analyze, and visualize these TaqPath N corrected Ct values 256 in all analyses.

257

258

Generalized additive modeling of the longitudinal C_t *distribution by region.* 259 After observing a population-level dip in the average C_t value recovered from our testing 260 platform, roughly coincident with the epidemic peak in the three regions of interest, we asked the broad question, what is the population level time-trend of SARS-CoV-2 C_t values across these 261 262 three regions? To address this question, we compiled all positive tests from the first date of 263 positive testing for each patient, recording the date, region, test, and target that corresponded to 264 each corrected C_t value, in addition to the numerical ID and the symptom status (asymptomatic, 265 symptomatic, or unknown) of the patient from which it was derived. Symptom statuses were 266 recorded by medical staff at the timepoint of sampling and merely indicated whether or not the patient presented with symptoms; thus, 'asymptomatic' classification did exclude the possibility 267 268 that the same patient reported symptoms at later or earlier timepoints across the course of 269 infection. The resulting data consisted of 8,055 discrete C_t values, corresponding to 5,280270 patients, most of whom were tested using multiple tests and/or gene targets of interest. Ct values 271 for these positive test results ranged from 6.36 to 39.91. When reprojected to TagPath N levels, 272 the range shifted from 7.82 to 39.99, such that 507 Ct values classed as "positive" by the cutoff thresholds on other platforms exceeded the $C_t <= 37$ threshold for positivity on the TaqPath 273 274 platform. These samples were nonetheless retained for generalized additive modeling (GAM) of 275 longitudinal Ct trends but GAM-projected Ct values still exceeding the TaqPath cutoff were later 276 excluded in mechanistic modeling of transmission trends fitted to positive data.

277 Using the mgcv package [36] in the R statistical program, we next fit a GAM in the 278 gaussian family to the response variable of corrected C_t value, incorporating a numerical 279 thinplate smoothing predictor of date, and random effects on the categorical variables of test 280 (Charity Berlin, Hong Kong, Da An, LightMix SarbeCoV, SarbeCoV TibMolBio, TaqPath, or 281 GeneXpert), target (E,N,Orf1a/b, or S), and individual patient ID. We refit the model to three 282 different subsets of the data, encompassing the Atsinanana and Analamanga regions, as well as 283 the entire National data as a whole. We then used the resulting fitted GAMs to simulate 284 population-level Ct distributions for each date in our dataset, excluding the effects of test and 285 target in the predict.gam function from mgcv. This produced a test- and target-controlled average 286 Ct estimate for each positive patient at the timepoint of sampling. We used these GAM-simulated 287 Ct distributions to carry out mechanistic model fitting in subsequent analyses, as described 288 below, excluding 15 patients with Ct projections >37, which exceeded the positive threshold for 289 the TaqPath N gene assay (our standard).

290

291

Generalized additive modeling of C_t value since time of infection onset.

292 To validate observations from the literature which indicate that the viral load and 293 corresponding C_t value follow a predictable trajectory after the onset of SARS-CoV-2 infection 294 [14,15] within our own study system, we next concentrated analyses on a subset of 4.822 Ct 295 values (corresponding to 2,842 unique samples derived from 2,404 unique patients), for which 296 the timing of symptom onset was also recorded. For each of these samples, we randomly drew a 297 corresponding incubation time from the literature-derived log-normal distribution above [30] to 298 approximate the timing of infection onset. To answer the question, how does C_t vary with time 299 since symptom onset?, we fit a GAM in the gaussian family to the resulting data with a response 300 variable of C_t and a numerical thinplate smoothing predictor of days since infection onset, as

well as random effects of test, target, and patient ID. After fitting, we used the predict.gam
function from the mgcv package, excluding the effects of target and test, to produce a
distribution of Ct values corresponding to times since symptom onset (one per each unique
patient ID). We used these Ct trajectories to estimate parameters for the within-host viral kinetics
model described in final methods section below.

306

307 *Generalized additive modeling of the relationship between* C_t *value and symptom status.*

308 We next asked the question, does C_t value vary in symptomatic vs. asymptomatic cases? 309 Our first investigation of this question required only reconsideration of the individual trajectory 310 GAM described above to include additional predictor variables of age and symptom status, in 311 addition to days since infection onset, target, and test. Since symptom status was recorded only at 312 the first timepoint of sampling for each individual, we limited our individual trajectory dataset to 313 a 4,072 datapoint subset of Ct values from 2,404 discrete patients reporting both date of 314 symptom/infection onset and symptom status at the timepoint of sampling; as mentioned previously, 'asymptomatic' classification in our dataset included patients reporting symptoms 315 316 from earlier or later timepoints prior to or following the sampling date. Thus, this GAM tested 317 whether symptom status and C_t value interacted merely as a function of the timing since 318 symptom onset (e.g. high C_t values were recovered from patients either very early or late in their 319 infection trajectory), or whether independent interactions between symptomatic vs. 320 asymptomatic infections and C_t were also present, while also controlling for age.

After observing results, we extended this analysis by applying another GAM in the gaussian family to a 7,937 datapoint subset of the data used to model longitudinal C_t trajectories at the National level, which additionally reported symptom status (symptomatic vs. asymptomatic) at the timepoint of first sampling for 5,202 unique patients. Corrected C_t values in this data subset ranged between 7.82 and 39.99. This GAM incorporated a response variable of C_t and random effects predictor smoothing terms of symptom status, test, target, and patient ID, as well as a numerical smoothing predictor for age of the infected patient.

328

329 *Estimating epidemic growth rates from cross-sectional C_t values.*

330 Finally, following newly-developed methods [12], we sought to estimate the epidemic 331 growth rate across our three regions of interest using cross-sectional C_t distributions and compare 332 these results against estimates derived from case count methods described above. To this end, we 333 first fit the within-host viral kinetics model described in Hay et al. 2020 to the test- and target-334 controlled C_t values produced from the above GAM describing C_t as a function of time since 335 infection. We used the resulting parameter estimates as informed priors (Table S1) which we 336 next incorporated into two population-level SARS-CoV-2 transmission models applied to our 337 time series data across the three Madagascar regions: a compartmental SEIR model and a more 338 flexible Gaussian process model [12]. Beyond the viral kinetics parameters, we adopted less-339 constrained priors from the original paper [12] for other epidemiological parameters included in 340 both population-level models (Table S1), then re-fit both transmission models in turn to crosssectional weekly Ct distributions derived from the Atsinanana, Analamanga, and National-level 341 342 datasets. We fit both models to each dataset using an MCMC algorithm derived from lazymeme 343 R-package [37], as described in the original paper [12], applying the default algorithm to the 344 Gaussian process fit and a parallel tempering algorithm able to accurately parse multimodal 345 posterior distributions to the SEIR fit. Four MCMC chains were run for 500,000 iterations in the 346 case of the Gaussian process model and three MCMC chains for 80,000 iterations each in the

case of the SEIR model, then evaluated for convergence via manual inspection of the resulting trace plots and verification that \hat{R} , the potential scale reduction factor, had a value <1.1 and the effective population size had a value >200 for all parameters estimated.

After confirming chain convergence, we computed epidemic growth rates from the resulting estimated infection time series and compared results with those derived using more traditional case count methods outlined above. Code and supporting datasets needed to reproduce all analyses are available for download on our opensource GitHub repository at:

- 354 github.com/carabrook/Mada-Ct-Distribute.
- 355

356 Results.

357 *Epidemic trajectories from case count data.*

The first wave of COVID-19 infections in Madagascar, between March and September 358 359 2020, was characterized by two subsequent outbreaks: one early, May 2020 peak centered in the 360 eastern port city of Toamasina (region Atsinanana), followed by a second peak in July centered 361 in the capital city of Antananarivo (region Analamanga) (Fig. 1) [1]. Estimation of the epidemic growth rate showed broad agreement in trends at both the national and regional levels, whether 362 363 computed from IPM testing data assuming perfect reporting of testing date, or from publicly 364 reported national data, including a reporting delay parameterized from a global opensource 365 database (Fig. 1) [33]. Since IPM data comprised just over 30% of nationally reported data 366 throughout the first six months of the Madagascar epidemic, this concurrence in growth rates 367 was unsurprising but nonetheless validates the applicability of the globally parameterized 368 reporting delay for use in Madagascar. In both datasets, we estimated the national level epidemic 369 growth rate to be increasing in the months preceding the two epidemic sub-peaks (in April and in 370 June) and declining beginning in mid-July after the last peak in national case counts (Fig. 1). 371 When IPM data were considered at the regional level, we discovered the April peak to be 372 concentrated in Atsinanana, preceding the Toamasina outbreak and the June peak to be 373 concentrated in Analamanga preceding the Antananarivo outbreak. Growth rate estimation from 374 publicly reported data confirmed this pattern for Analamanga but was not possible for the

375 Atsinanana region due to a lack of clarity in regional reporting.

376

377 Standardizing C_t values across tests and targets.

All RT-qPCR platforms used in our laboratory demonstrated increases in C_t value corresponding to 10-fold dilutions of RNA extracted from the original virus isolate (Table S2), though the estimated slope and y-intercept of each regression varied across the tests and targets considered, with the steepest slope recovered from GeneXpert N-gene tests and the shallowest from the Hong Kong ORF1a/b kits (Fig. S1, Table S3). We used the corresponding slope and yintercept for each test and platform to transform C_t values in all subsequent analyses into values predicted for a TaqPath N-gene platform.

385

386 Longitudinal population-level trends in SARS-CoV-2 Ct values across the epidemic wave.

387 We observed a population-level dip in C_t values obtained from our SARS-CoV-2 RT-

qPCR platform concurrent with the regional peak in cases in May for Atsinanana and June for

Analamanga, with both peaks observable in the National data (Fig. 2A). GAMs fit to Atsinanana,

Analamanga, and National data subsets explained, respectively, 98.8, 98.9, and 98.9% of the

deviation in the data (Table S4). All three GAMs demonstrated statistically significant effects of

date, test, and individual patient ID, which contributed to the total deviance capture by each

393 model. GAMs fit to the Analamanga and National data subsets showed an additional significant 394 effect of target on the Ct value. Partial effects plots were computed from the resulting GAMs 395 (Fig. S2) following methods described in [38] and demonstrated no significant effects of any 396 particular test or target gene. In general, most variation in C_t value beyond that of the individual 397 patient was driven by the significant effect of date across all regions (Table S4).

398



399 400 Fig. 2. RT-qPCR SARS-CoV-2 Ct value as a biomarker of population-level epidemic pace and individual 401 infection trajectory. (A.) Population-level SARS-CoV-2 corrected Ct values from IPM RT-qPCR platform across 402 three Madagascar regions from March-September 2020. Ct values are colored by the test and shaped by the target 403 from which they were derived (legend), though note that all C_t values were first corrected to TaqPath N gene range. 404 Black trend line gives the output from a gaussian GAM fit to these data (Table S4), excluding the effects of target 405 and test, which were also included as predictors in the model; 95% confidence intervals by standard error are shown 406 in translucent shading. Partial effects of each predictor are visualized in Fig. S2. Righthand plots visualize partial 407 effects of (**B**.) days since infection, (**C**.) patient age, and (**D**.) patient symptom status on C_t value from our individual 408 trajectory GAM (Table S5). Significant predictors are depicted in light blue and non-significant in gray (Table S5).

409

410 Individual trends in SARS-CoV-2 C_t values across the trajectory of infection.

The SARS-CoV-2 Ct value also demonstrated a predictable trajectory from the timing of 411 onset of infection. Our GAM fit to data reporting a date of symptom onset (which we converted 412

413 to a date of infection onset) and incorporating a predictor smoothing term of days since infection

onset, and random effects of test, target, and patient ID explained 92.7% of the deviance in the 414

415 data and demonstrated statistically significant effects of all predictor variables, including days

416 since infection onset (Table S5). These findings confirmed that C_t value can be used as a

417 biomarker of time since infection, validating the applicability of methods outlined in [12] for our

418 Madagascar data.

419 420 *Relationship between symptom status and SARS-CoV-2 Ct value.*

421 As an extension of the individual trajectory analysis, we hypothesized that Ct value 422 would likely be linked to symptom status, since many infection trajectories begin with a brief 423 presymptomatic phase, progress to symptom presentation, then become asymptomatic during 424 recovery [14,15]. The first GAM we employed to address this question considered age and 425 symptom status as additional predictor variables in our individual trajectory analysis. This final 426 GAM explained 98.5% of the deviation in the data and included significant effects of days since 427 infection onset, symptom status, test, target, and patient ID (Table S5). Despite the significance 428 of symptom status as a predictor variable in the GAM overall, partial effects plots demonstrated 429 no significant association between asymptomatic status and high Ct values or symptomatic status 430 and low Ct values, while controlling for age (Fig. 2B, 2C, 2D). These results suggest that, in our 431 dataset, Ct value varies predictably with an individual's infection trajectory regardless of 432 symptom classification or age of the patient, further validating its adoption as a robust biomarker

433 of time since infection (Table S5).

434 We additionally extended this analysis to our National-level Ct dataset, including a 435 predictor variable of symptom status, in addition to test, target, patient age, and patient ID in 436 longitudinal GAMs. This model explained 98.9% of the deviation witnessed in the data, 437 including significant effects of test, target, patient ID, and symptom status (Table S6). Test and 438 target were here included as control variates only and cannot be considered for prediction, as 439 both co-varied with date, which was not used as a predictor in this model. In this model, partial 440 effects plots indicated a significant association of asymptomatic status with high C_t values and 441 symptomatic status with low Ct values (Fig. S3), even when controlling for effects of age; as this 442 larger dataset did not report date of symptom/infection onset, it is likely that this association co-443 varied with the timing of infection onset, suggesting that previous reports of a high proportion of 444 asymptomatic infections in Madagascar [1] could reflect a high proportion of pre- or post-445 symptomatic infections.

446

447 *Epidemiological dynamics inferred from cross-sectional C_t distributions.*

448 After confirming the predictable pattern of C_t value across an individual's infection 449 trajectory, and the predictable decline in population-level C_t in conjunction with the epidemic 450 peak, we used our individual trajectory GAM to simulate a distribution of Ct values across a 50-451 day duration of infection and fit the within-host viral kinetics model described in [12] to the 452 resulting data (Fig. S4). The model demonstrated a good fit to the data, and estimated posterior 453 distributions for viral kinetics parameters were largely on par with those used previously in 454 models of SARS-CoV-2 dynamics in Massachusetts, though the modal Ct value at peak viral 455 load was slightly lower in our Madagascar dataset (Fig S4; Table S1).

456 After fitting the within-host model, we next used longitudinal population-level GAMs 457 (Fig. S2) to generate weekly cross-sectional C_t distributions, controlled for test and target, across 458 our three regions of interest. As expected, weekly cross-sectional C_t distributions demonstrated a 459 shift across the duration of the epidemic wave; with lower C_t values temporally correlated with 460 high growth rates estimated from case count data (Fig. 3).



462 463 Fig. 3. Population-level C_t distribution reflects epidemic dynamics of the first wave of COVID-19 across three 464 Madagascar regions. (A.) Simulated weekly Ct distributions by Madagascar region, derived from population-level 465 longitudinal GAMs (Fig. 2A), excluding random effects of test and target. (B.) Higher skew and lower median C_t 466 from each cross-sectional Ct distribution in (A.) were loosely associated with higher epidemic growth rates from the 467 corresponding week, here derived from EpiNow2 estimation from IPM case count data (Fig. 1B.) (C.) Cross-468 sectional Ct distributions from Analamanga time series in (A.) were fit via Gaussian process (GP) and SEIR 469 mechanistic models incorporating a within-host viral kinetics model. Modeled Ct distributions are shown as solid 470 lines (GP=red; SEIR=purple), with 95% quantiles in surrounding sheer shading. Both models effectively recapture 471 the shape of the Ct histogram as it changes (skews left) across the duration of the first epidemic wave. Model fits to 472 the full time series of Ct histograms across all three regions are visualized in Fig. S7, S8, S9. 473

474 Finally, we used the viral kinetics posterior distributions resulting from the within-host 475 viral kinetics model fit as prior inputs into SEIR and Gaussian process population-level 476 epidemiological models, which we fit to the weekly cross-sectional C_t data. MCMC chains 477 generated in the fitting process demonstrated good convergence (Fig. S5, Table S7, Table S8) 478 and produced posterior distributions for all parameters on par with those estimated in previous 479 work (Table S1, Fig. S6), which effectively recaptured cross-sectional C_t value histograms across 480 the target timeseries in all three regions (Fig. 3, Fig. S7-S9) [12]. From the resulting fitted 481 models, we simulated epidemic incidence curves, which we used to compute growth rate 482 estimates across the duration of the first epidemic wave in each of the three regions (Fig. 4). We 483 compared these estimates to growth rates inferred from case count data; patterns from both SEIR 484 and Gaussian process models were largely complementary, though the more flexible Gaussian process model demonstrated less extreme variation in epidemic growth rate. Both C_{t} -model fits 485 demonstrated similar patterns to epidemic trajectories estimated from incidence data, with 486 increasing growth rates in the months preceding both epidemic sub-peaks (April and June) and 487 decreasing growth rates beginning in July. Nonetheless, growth rate estimates derived from the 488 489 C_t model slightly preceded those estimated from case count data. The C_t model fits further predicted uncertainty in growth rate directionality towards the end of the study period for the 490

- 491 Analamanga and National-level data, while incidence estimation projected decreasing cases at
- 492 this time. This finding suggests that cross-sectional Ct distributions indicated a possible epidemic
- resurgence which was overlooked by growth rates estimated from declining incidence. If
- 494 incidence declined in part due to declining surveillance, as was the reality at the end of
- 495 Madagascar's first epidemic wave [1], only the Ct method remained robust to the possibility of
- 496 epidemic renewal.



497
498
498
498
498
498
498
498
498
499
498
499
498
499
490
490
490
490
490
490
491
491
491
492
493
494
494
495
495
495
496
497
497
497
498
499
498
499
498
499
498
499
498
499
498
499
498
499
499
498
499
490
498
499
498
498
499
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498
498

500 from March-September 2020, estimated from IPM (blue) and publicly reported (gray) case count data using 501 EpiNow2 [28] with estimates derived from Gaussian process (GP; red) mechanistic model fit to the time series of C_t 502 distributions (Fig. 3A). Median growth rates are shown as solid lines, with 50% quantile on case-based estimates 503 and 95% quantile of the posterior distributions from C_t -based estimates in corresponding sheer shading. (B.) Growth 504 rate estimates from individual SEIR Ct-model fits to each Ct-distribution shown in Fig. 3A; median growth rates are 505 given as horizontal dashes, with the 95, 70, 50, and 20% of the posterior distribution indicated by progressively 506 darker coloring. Estimates >0 (indicating growing epidemics) are depicted in gold and <0 (indicating declining 507 epidemics) in purples. (C.) Raw case count data from the time series (dark=IPM data; light=publicly reported data) 508 is shown for reference.

509

510 Conclusions.

511 Real-time estimation of epidemiological parameters, including the time-varying effective 512 reproduction number, R_t , and the related instantaneous epidemic growth rate, r, has played an 513 important role in guiding public health interventions and policies across many epidemic 514 outbreaks, including COVID-19 [39–41]. In Madagascar, an opensource platform [11] was 515 developed shortly after the introduction of COVID-19 in March 2020, to collate and visualize

- developed shortly after the introduction of COVID-19 in March 2020, to collate and visualiz publicly reported data and estimate R_t using traditional methods applied to daily reported
- 517 incidence [28,29]. We here compare the results from this platform applied to the first epidemic
- 517 Incluence [26,29]. We here compare the results from this platform applied to the first epidemic 518 were in Medagasser, with new estimates of the time verying epidemic growth rate epidemic
- 518 wave in Madagascar, with new estimates of the time-varying epidemic growth rate applied to our

519 own laboratory data across the first epidemic wave—including those derived using a novel 520 method based on the cross-sectional C_t value distribution at the time of sampling [12].

521 We find our new estimates to be largely congruent with those predicted from publicly 522 reported data, demonstrating a pattern of increasing epidemic growth rates prior to a peak in 523 cases, which occurred first in May 2020 in the Atsinanana region, followed by a second outbreak 524 in July 2020 in the Analamanga region. Critically, our growth rate estimates derived using novel 525 methods applied to the Ct distribution over time slightly precede those estimated from incidence 526 data. As previous work has demonstrated Ct estimation to offer a more robust approximation of 527 true dynamics under limited surveillance scenarios [12], these findings suggest that incidence-528 based methods to estimate epidemic trajectories in Madagascar may be underestimating the true 529 pace of the epidemic, likely as a result of underreporting. Additionally, C_t-based methods 530 adopted by a single laboratory allow for estimation of epidemic growth rates even in the absence 531 of publicly reported case counts: in October 2020, the Malagasy Ministry of Health shifted its 532 daily COVID-19 case notifications to weekly, interfering with incidence-based approaches to 533 estimate epidemic trajectories [11]. Ct-based approaches, instead, should be robust to this 534 variation in reporting, offering a powerful tool for public health efforts in low surveillance 535 settings. Indeed, our analysis demonstrates that C_t -based epidemic growth rates show uncertain 536 directionality towards the end of the first wave of COVID-19 in Madagascar, presaging eventual 537 epidemic resurgence, while incidence-based rates categorically declined due to both truly 538 declining cases and declining surveillance. Incidence-based growth rate estimation ceased during 539 the continued limited surveillance period from October 2020 through March 2021 [11]; had Ct-540 based methods been available at the time, it is possible that the current second wave could have 541 been predicted and mitigated by earlier rollout of public health interventions.

542 Statistical analysis of our C_t data indicates that C_t values vary predictably with days since 543 onset of infection, allowing viral kinetics data to be leveraged for population-level estimation of 544 epidemiological patterns. In our system, this pattern held even after controlling for the effects of 545 age and symptom status on the Ct trajectory, further validating the applicability of Ct value as an 546 indicator of time since infection. Nonetheless, in future work, it mat be possible to fit unique 547 viral kinetics trajectories for different classes of people; for example, older age cohorts or 548 cohorts of people infected with more transmissible variants may be better represented by lower 549 average C_t trajectories than the population as a whole [15,42]. Our application of generalized 550 additive models to both individual infection trajectory and population-level Ct distributions 551 offers an effective means by which to control for variation in test and target across diverse RT-552 qPCR platforms to generate C_t values for epidemiological inference which represent a reliable 553 average of population-level patterns overall.

554 We acknowledge the limitations of our current method, especially as it relates to testing 555 biases. During the earliest phases of the epidemic in Madagascar, testing resources were limited in our laboratory, which may have biased sample intake towards high-viral-load, low-Ct-value 556 557 cases that could bias epidemiological inference towards increasing growth rates even after the 558 epidemic has, in reality, already begun to decline. As the epidemic ensued, however, the 559 Madagascar Ministry of Health focused sampling on symptomatic patients and their suspected 560 contacts, leading to a high proportion (56.6%) of reported asymptomatic infections in our dataset 561 [1], which may have instead prematurely biased inference towards a declining epidemic. 562 Nonetheless, our Ct-based projections of epidemic trajectories do not appear to underestimate 563 realized trends, suggesting that our method was robust to these inconsistencies.

We apply a novel method leveraging within-host viral load data that is currently largely overlooked in the epidemiological literature to describe the dynamics of the first wave of COVID-19 in Madagascar. Our approach validates an important new tool for epidemiological inference of ongoing epidemics, particularly applicable to limited surveillance settings characteristic of many lower- and middle- income countries. We advocate for public release of real time data describing the Ct value distribution, in addition to daily case counts, to improve epidemiological inference to guide public health response and intervention.

Acknowledgements

This work was supported by the US National Institutes of Health [1R01AI29822-01]; the Bill & Melinda Gates Foundation, Seattle, WA [GCE OPP1211841]; and the Innovative Genomics Institute at UC Berkeley, Berkeley, CA [COVID-19 Rapid Response Grant]. The authors thank

- Malavika Rajeev, Tanjona Ramiadantsoa, and Benjamin Rice for help in establishing the Madagascar COVID-19 dashboard.

610 **References**

- R. Randremanana, S. Andriamandimby, J.M. Rakotondramanga, N. Razanajatovo, R.
 Mangahasimbola, T. Randriambolamanantsoa, H. Ranaivoson, H. Rabemananjara, I.
 Razanajatovo, J. Rabarison, C. Brook, F. Rakotomanana, R. Rabetombosoa, H.
 Razafimanjato, V. Ahyong, V. Raharinosy, V. Raharimanga, S. Raharinantoanina, M.
 Randrianarisoa, B. Bernardson, L. Randrianasolo, Z. Randriamanantany, J. Heraud, C.Z.
 Biohub, The COVID-19 Epidemic in Madagascar: clinical description and laboratory
- 618 results of the first wave, March-September 2020, Influenza Other Respi. Viruses. 00
 619 (2021) 1–12.
- M.H. Chitwood, M. Russi, K. Gunasekera, J. Havumaki, V.E. Pitzer, J.L. Warren, D.M.
 Weinberger, T. Cohen, N.A. Menzies, Menzies3, Bayesian nowcasting with adjustment
 for delayed and incomplete reporting to estimate COVID-19 infections in the United
 States, MedRxiv. 20 (2020) 1–6. doi:10.18907/jjsre.20.7_624_5.
- 624 [3] D.P. Oran, E.J. Topol, Prevalence of asymptomatic SARS-CoV-2 infection: A narrative review, Ann. Intern. Med. Med. 173 (2020) 362–367. doi:10.7326/M20-3012.
- K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, Estimating the asymptomatic
 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess
 cruise ship, Yokohama, Japan, 2020, Eurosurveillance. 25 (2020) 1–5. doi:10.2807/15607917.ES.2020.25.10.2000180.
- H. Nishiura, T. Kobayashi, T. Miyama, A. Suzuki, S. mok Jung, K. Hayashi, R. Kinoshita,
 Y. Yang, B. Yuan, A.R. Akhmetzhanov, N.M. Linton, Estimation of the asymptomatic
 ratio of novel coronavirus infections (COVID-19), Int. J. Infect. Dis. 94 (2020) 154–155.
 doi:10.1016/j.ijid.2020.03.020.
- [6] T.A. Treibel, C. Manisty, M. Burton, Á. McKnight, J. Lambourne, J.B. Augusto, X.
 Couto-Parada, T. Cutino-Moguel, M. Noursadeghi, J.C. Moon, COVID-19: PCR
 screening of asymptomatic health-care workers at London hospital, Lancet. 395 (2020)
 1608–1610. doi:10.1016/S0140-6736(20)31100-4.
- S. Abbott, J. Hellewell, R.N. Thompson, K. Sherratt, H.P. Gibbs, N.I. Bosse, J.D.
 Munday, S. Meakin, E.L. Doughty, J.Y. Chun, Y.-W.D. Chan, F. Finger, P. Campbell, A.
 Endo, C.A.B. Pearson, A. Gimma, T. Russell, C.C. modelling Group, S. Flasche, A.J.
 Kucharski, R.M. Eggo, S. Funk, Temporal variation in transmission during the COVID-19
 outbreak, (n.d.).
- [8] K.M. Gostic, L. McGough, E.B. Baskerville, S. Abbott, K. Joshi, C. Tedijanto, R. Kahn,
 R. Niehus, A. Hay, P.M. De Salazar, J. Hellewell, S. Meakin, J.D. Munday, N.I. Bosse, K.
 Sherrat, R.N. Thompson, L.F. White, J.S. Huisman, J. Scire, S. Bonhoeffer, T. Stadler, J.
 Wallinga, S. Funk, M. Lipsitch, S. Cobey, Practical considerations for measuring the
 effective reproductive number, Rt, PLoS Comput. Biol. 16 (2020) e1008409.
 doi:10.1371/journal.pcbi.1008409.
- 649 [9] J. Wallinga, M. Lipsitch, How generation intervals shape the relationship between growth
 650 rates and reproductive numbers, Proc. R. Soc. B-Biological Sci. 274 (2007) 599–604.
 651 doi:10.1098/rspb.2006.3754.
- [10] S.W. Park, B.M. Bolker, D. Champredon, D.J.D. Earn, M. Li, J.S. Weitz, B.T. Grenfell, J.
 Dushoff, Reconciling early-outbreak estimates of the basic reproductive number and its
 uncertainty : framework and applications to the novel coronavirus (SARS-CoV-2)
 outbreak, J. R. Soc. Interface. 17 (2020) 20200144.

- F. Rasambainarivo, T. Ramiadantsoa, S. Randrianarisoa, M. Rajeev, B. Rice, C.J. Metcalf,
 COVID-19 Madagascar Dashboard, (2020).
- [12] J.A. Hay, L. Kennedy-Shaffer, S. Kanjilal, N.J. Lennon, S.B. Gabriel, M. Lipsitch, M.J.
 Mina, Estimating epidemiologic dynamics from cross-sectional viral load distributions, MedRxiv. (2021).
- 661 [13] M.R. Tom, M.J. Mina, To interpret the SARS-CoV-2 test, consider the cycle threshold
 662 value, Clin. Infect. Dis. 71 (2020) 2252–2254. doi:10.1093/cid/ciaa619.
- [14] Y. Chen, L. Li, SARS-CoV-2: virus dynamics and host response, Lancet Infect. Dis. 2019
 (2020) 2019–2020. doi:10.1016/S1473-3099(20)30235-8.
- 665 [15] D. Jacot, G. Greub, K. Jaton, O. Opota, Viral load of SARS-CoV-2 across patients and
 666 compared to other respiratory viruses, Microbes Infect. 22 (2020) 617–621.
 667 doi:10.1016/j.micinf.2020.08.004.
- B. Borremans, A. Gamble, K.C. Prager, S.K. Helman, A.M. McClain, C. Cox, V. Savage,
 J.O. Lloyd-Smith, Quantifying antibody kinetics and rna detection during early-phase
 SARS-CoV-2 infection by time since symptom onset, Elife. 9 (2020) 1–27.
 doi:10.7554/ELIFE.60122.
- 672 [17] B. Borremans, N. Hens, P. Beutels, H. Leirs, J. Reijniers, Estimating time of infection using prior serological and individual information can greatly improve incidence
 674 estimation of human and wildlife infections, PLoS Comput. Biol. 12 (2016) e1004882.
 675 doi:10.1371/journal.pcbi.1004882.
- [18] J.A. Hay, A. Minter, K.E.C. Ainslie, J. Lessler, B. Yang, D.A.T. Cummings, A.J.
 Kucharski, S. Riley, An open source tool to infer epidemiological and immunological dynamics from serological data: Serosolver, PLoS Comput. Biol. 16 (2020) 1–24.
 doi:10.1371/journal.pcbi.1007840.
- [19] H. Salje, D.A.T. Cummings, I. Rodriguez-barraquer, L.C. Katzelnick, J. Lessler, C.
 Klungthong, B. Thaisomboonsuk, A. Nisalak, A. Weg, D. Ellison, L. Macareo,
 Reconstruction of antibody dynamics and infection histories to evaluate dengue risk,
 Nature. 557 (2018) 719–723. http://dx.doi.org/10.1038/s41586-018-0157-4.
- [20] J. Wallinga, M. Lipsitch, How generation intervals shape the relationship between growth
 rates and reproductive numbers, Proc. R. Soc. B Biol. Sci. 274 (2007) 599–604.
 doi:10.1098/rspb.2006.3754.
- 687 [21] G. Rydevik, G.T. Innocent, G. Marion, R.S. Davidson, P.C.L. White, C. Billinis, P.
 688 Barrow, P.P.C. Mertens, D. Gavier-Widén, M.R. Hutchings, Using Combined Diagnostic
 689 Test Results to Hindcast Trends of Infection from Cross-Sectional Data, PLoS Comput.
 690 Biol. 12 (2016) 1–19. doi:10.1371/journal.pcbi.1004901.
- M. Moraz, D. Jacot, M. Papadimitriou-Olivgeris, L. Senn, G. Greub, K. Jaton, O. Opota,
 Universal admission screening strategy for COVID-19 highlighted the clinical importance
 of reporting SARS-CoV-2 viral loads, New Microbes New Infect. 38 (2020) 100820.
 doi:10.1016/j.nmni.2020.100820.
- 695 [23] A.S. Walker, E. Pritchard, T. House, J. V Robotham, P.J. Birrell, J.I. Bell, J.N. Newton, J.
 696 Farrar, I. Diamond, R. Studley, J. Hay, Viral load in community SARS-CoV-2 cases
 697 varies widely and temporally, (2020).
- 698 [24] I.N. de la S. Madagascar., Troisieme Recensement General de la Population et de
 699 L'Habitation (RGPH-3) Resultats Provisoires, 2018.
- 700 [25] The World Health Organization (WHO). Molecular assays to diagnose COVID-19:
- 701 Summary table of available protocols 2020, (n.d.). https://www.who.int/publi catio

702 ns/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols. 703 V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K.W. Chu, T. Bleicker, [26] 704 S. Brünink, J. Schneider, M.L. Schmidt, D.G.J.C. Mulders, B.L. Haagmans, B. Van Der 705 Veer, S. Van Den Brink, L. Wijsman, G. Goderski, J.L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, M.P.G. Koopmans, C. Drosten, Detection of 2019 novel 706 707 coronavirus (2019-nCoV) by real-time RT-PCR, Eurosurveillance. 25 (2020). 708 doi:10.2807/1560-7917.ES.2020.25.3.2000045. 709 D.K.W. Chu, Y. Pan, S.M.S. Cheng, K.P.Y. Hui, P. Krishnan, Y. Liu, D.Y.M. Ng, C.K.C. [27] 710 Wan, P. Yang, Q. Wang, M. Peiris, L.L.M. Poon, Molecular diagnosis of a novel 711 coronavirus (2019-nCoV) causing an outbreak of pneumonia, Clin. Chem. 66 (2020) 549-712 555. doi:10.1093/clinchem/hvaa029. 713 S. Abbott, J. Hellewell, K. Sherratt, K. Gostic, J. Hickson, H.S. Badr, M. DeWitt, R. [28] 714 Thompson, EpiForecasts, S. Funk, EpiNow2: Estimate real-time case counts and time-715 varying epidemiological parameters, (2020). A. Cori, N.M. Ferguson, C. Fraser, S. Cauchemez, A new framework and software to 716 [29] 717 estimate time-varying reproduction numbers during epidemics, Am. J. Epidemiol. 178 718 (2013) 1505–1512. doi:10.1093/aje/kwt133. 719 S.A. Lauer, K.H. Grantz, Q. Bi, F.K. Jones, Q. Zheng, H.R. Meredith, A.S. Azman, N.G. [30] 720 Reich, J. Lessler, The incubation period of coronavirus disease 2019 (CoVID-19) from 721 publicly reported confirmed cases: Estimation and application, Ann. Intern. Med. 172 722 (2020) 577-582. doi:10.7326/M20-0504. 723 T. Ganyani, C. Kremer, D. Chen, A. Torneri, C. Faes, J. Wallinga, N. Hens, Estimating [31] 724 the generation interval for coronavirus disease (COVID-19) based on symptom onset data, 725 March 2020, Eurosurveillance. 25 (2020) 1-8. doi:10.2807/1560-726 7917.ES.2020.25.17.2000257. 727 S. Abbott, J. Hellewell, R.N. Thompson, K. Sherratt, H.P. Gibbs, N.I. Bosse, J.D. [32] 728 Munday, S. Meakin, E.L. Doughty, J.Y. Chun, Y.D. Chan, F. Finger, P. Campbell, A. 729 Endo, C.A.B. Pearson, A. Gimma, T. Russell, C. Covid, S. Flasche, A.J. Kucharski, R.M. 730 Eggo, S. Funk, Estimating the time-varying reproduction number of SARS-CoV-2 using 731 national and subnational case counts, Wellcome Open Res. (2021) 1-10. 732 B. Xu, B. Gutierrez, S. Mekaru, K. Sewalk, L. Goodwin, A. Loskill, E.L. Cohn, Y. [33] 733 Hswen, S.C. Hill, M.M. Cobo, A.E. Zarebski, S. Li, C.H. Wu, E. Hulland, J.D. Morgan, L. 734 Wang, K. O'Brien, S.V. V. Scarpino, J.S. Brownstein, O.G. Pybus, D.M. Pigott, M.U.G. 735 Kraemer, Epidemiological data from the COVID-19 outbreak, real-time case information, 736 Sci. Data. 7 (2020) 1-6. doi:10.1038/s41597-020-0448-0. 737 H. Auerswald, S. Yann, S. Dul, S. In, P. Dussart, N.J. Martin, E.A. Karlsson, J.A. Garcia-[34] 738 Rivera, Assessment of inactivation procedures for SARS-CoV-2, J. Gen. Virol. 102 739 (2021) 1-5. doi:10.1099/JGV.0.001539. 740 [35] D. Bates, M. Mächler, B.M. Bolker, S.C. Walker, Fitting linear mixed-effects models 741 using lme4, J. Stat. Softw. 67 (2015) 1–48. doi:10.18637/jss.v067.i01. 742 S.N. Wood, mgcv: GAMs and Generalized Ridge Regression for R, R News. 1/2 (2001) [36] 743 20-24.744 J. Hay, lazymcmc, (2020). https://github.com/jameshay218/lazymcmc. [37] 745 N. Mollentze, D.G. Streicker, Viral zoonotic risk is homogenous among taxonomic orders [38] 746 of mammalian and avian reservoir hosts, Proc. Natl. Acad. Sci. (2020) 1-8. 747 doi:10.1073/pnas.1919176117.

- [39] S. Cauchemez, P.Y. Boëlle, C.A. Donnelly, N.M. Ferguson, G. Thomas, G.M. Leung, A.J.
 Hedley, R.M. Anderson, A.J. Valleron, Real-time estimates in early detection of SARS,
 Emerg. Infect. Dis. 12 (2006) 110–113. doi:10.3201/eid1201.050593.
- [40] A.J. Kucharski, T.W. Russell, C. Diamond, Y. Liu, J. Edmunds, S. Funk, R.M. Eggo, F.
 Sun, M. Jit, J.D. Munday, N. Davies, A. Gimma, K. van Zandvoort, H. Gibbs, J.
 Hellewell, C.I. Jarvis, S. Clifford, B.J. Quilty, N.I. Bosse, S. Abbott, P. Klepac, S.
 Flasche, Early dynamics of transmission and control of COVID-19: a mathematical
 modelling study, Lancet Infect. Dis. 20 (2020) 553–558. doi:10.1016/S14733099(20)30144-4.
- A. Pan, L. Liu, C. Wang, H. Guo, X. Hao, Q. Wang, J. Huang, N. He, H. Yu, X. Lin, S.
 Wei, T. Wu, Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China, JAMA - J. Am. Med. Assoc. 323 (2020) 1915– 1923. doi:10.1001/jama.2020.6130.
- [42] M. Kidd, A. Richter, A. Best, N. Cumley, J. Mirza, B. Percival, M. Mayhew, O. Megram,
 F. Ashford, T. White, E. Moles-Garcia, L. Crawford, A. Bosworth, S.F. Atabani, T. Plant,
 A. McNally, S-Variant SARS-CoV-2 lineage B1.1.7 is associated with significantly
 higher viral load in samples tested by TaqPath Polymerase Chain Reaction, J. Infect. Dis.
 223 (2021). doi:10.1093/infdis/jiab082.





Fig. S1. Ct-dilution curves of RT-qPCR tests in tissue culture. RNA isolates from three
 patients positive with comparable Ct values for SARS-CoV-2 infection underwent serial

dilutions (x-axis) RT-qPCR assay (y-axis) across six RT-qPCR platforms used in our laboratory

during the first wave of the COVID-19 epidemic (Table S2). We fit linear mixed effect
 regression models in the lme4 R package [35] to the resulting dilution series across multiple runs

and replicates (shapes, colors) for each isolation to establish a trend line (lines and equations).
We used the resulting slope and y-intercept (Table S3) to standardize all Ct values in our dataset
in terms of TaqPath N-gene assays for downstream analysis.



818 Fig. S2. Partial effects of test, target, and date on SARS-CoV-2 Ct values across three

Madagascar regions. Partial effects of GAMs fitted to longitudinal Ct data from (A.,B.,C.)
Atsinanana region, (D.,E.,F.) Analamanga region and (G.,H.,I.) National data. Model outputs
are summarized in Table S4 and visualized in Fig. 2A. (main text). Significant partial effects
determined by holding all other variables constant (see [38] for methods) are depicted in blue
and insignificant partial effects in gray. Columns demonstrated relative effects of RT-qPCR test
(A.,D.,G.), target gene (B.,E.,H), and date (C.,F.,I.). Note that patient ID was also included in
each model as a (significant) random effect.



^{age}
Fig. S3. Partial effects of age and symptom status from population-level GAM. Partial

effects of GAM fitted to national Ct data with response variable of correct C_t and predictor

840 smoothing terms of test, target, and patient ID (as random effect controls) as well as (A.) age and

841 (**B**.) symptom status. Model outputs are summarized in Table S6. Significance is indicated by

842 blue shading: the significant effect of symptom status on Ct is likely the result of time since

843 onset of infection (i.e. 'asymptomatic' patients were either very early or very late in their

844 infection trajectory), which was not specified in these data.

845

846



848

849 Fig. S4. Fitting the within-host viral kinetics model to Madagascar data. Figure recapitulates Fig. S2 from [12] for our Madagascar data. The thick blue line in (A.) gives the fitted viral load 850 851 trajectory for the Madagascar data output from the individual trajectory GAM summarized in 852 Table S5 but excluding the effect of test and PCR-target. Madagascar data are shown as translucent colors in the background. Thin blue lines surrounding the thick line are trajectories 853 854 from prior draws within the 95% quantile, and violin plots show the distribution of detectable Ct 855 values post infection inferred from the fitted trajectory (blue line). As in [12], violins are colored by the proportion of Ct values above the limit of PCR detection (10^3 RNA cp/µl). Panel (B.) 856 shows the least-squares based fit (colored line) to the proportion of patients with detectable 857 858 SARS-CoV-2 in upper respiratory tract samples on each day post symptom onset from 859 Borremans et al. [16]. As in [12], black dots and lines show proportion positive and 95% 860 confidence intervals. Faint grey lines show proportion detectable over time from prior draws, and 861 faint grey ribbon shows 95% quantiles. Panel (C.) gives the assumed prior densities for viral 862 kinetics model parameters fit to Madagascar data (Table S1). 863



866 Fig. S5. Example trace plots for MCMC-fit of Gaussian process and SEIR Ct-models. Trace plots returned from MCMC fitting of (A.) Gaussian process (4-chains, standard MCMC) and (B.) 867 mechanistic SEIR models (3 chains, parallel tempering MCMC) to Madagascar National-level 868 time series of Ct distributions. Traces in (B.) show results from fitting to timepoint 77, the Ct 869 870 distribution from the week of April 27, 2020. Parameter details are given in Table S1. All traces 871 show good convergence, but as in [12], we observed that SEIR models demonstrated clear multi-872 modality in some parameter distributions, chiefly R_0 and t_0 . Data can be explained by either high 873 R_0 and low t_0 or low R_0 and high t_0 .

- 874
- 875
- 876
- 877



Fig. S6. Posterior distributions for fitted SEIR and Gaussian process models to

- 881 Madagascar Ct timeseries. Posterior distributions for all parameters inferred from MCMC
- fitting for (A.) Gaussian process (4-chains, standard MCMC) and (B.) mechanistic SEIR models
- 883 (3 chains, parallel tempering MCMC) to Madagascar National-level time series of Ct
- distributions. Parameter details are given in Table S1. As in Fig. S5, distributions in (B.) show
- results from fitting to timepoint 77, the Ct distribution from the week of April 27, 2020.
- 886 Multimodality in R_0 and t_0 is also evident here: data can be explained by either high R_0 and low t_0 887 or low R_0 and high t_0 .
- 888
- 889
- 890
- 891
- 892



Fig. S7. Gaussian process and SEIR Ct-model fits to cross-sectional histograms of Ct values
across the Atsinanana time series. Extension of Fig. 3C (main text) depicts the weekly
histogram of Ct values from the National timeseries in blue, and the resulting Ct distributions at
each timepoint from fitted Gaussian process (red) and SEIR (purple) models. Thick line gives the
median of distribution for each fit and translucent shading corresponds to the 95% quantiles.



911

912 Fig. S8. Gaussian process and SEIR Ct-model fits to cross-sectional histograms of Ct values

913 across the Analamanga time series. Extension of Fig. 3C (main text) depicts the weekly

histogram of Ct values from the Analamang timeseries in green, and the resulting Ct

915 distributions at each timepoint from fitted Gaussian process (red) and SEIR (purple) models.

916 Thick line gives the median of distribution for each fit and translucent shading corresponds to the917 95% quantiles.



Fig. S9. Gaussian process and SEIR Ct-model fits to cross-sectional histograms of Ct values
across the Atsinanana time series. Extension of Fig. 3C (main text) depicts the weekly

histogram of Ct values from the Atsinanana timeseries in red, and the resulting Ct distributions at
each timepoint from fitted Gaussian process (red) and SEIR (purple) models. Thick line gives the
median of distribution for each fit and translucent shading corresponds to the 95% quantiles.

936 **Supplementary Table Captions.**

937

938 Table S1. Model parameters (for viral kinetics + SEIR + Gaussian process models). Fixed

939 and estimated parameters and corresponding descriptions for all parameters used in viral 940 kinetics, SEIR, and Gaussian process models fit to cross-sectional Ct distributions across all three 941 regions.

942

943 Table S2. Dilution series of Ct value returned from disparate RT-qPCR platforms

944 inoculated with three virus isolates. Raw data from tissue culture inoculations, showing C_t 945 value resulting from RNA extracted after virus isolate inoculations in cell culture. Data are 946 organized by the test and target used to assay each replicate of each isolate across the dilution 947 series.

948

949 Table S3. Fitted linear mixed effect regression models to tissue culture inoculations in

- 950 **Table S2.** Slopes and v-intercepts of linear mixed effects regression models fit to tissue culture
- 951 dilutions series in Table S2. Regression lines are visualized in Fig. S1; note that the predictor

952 variable of "dilution", a proxy for viral load, is modeled on a log10 scale.

953

954 Table S4. Summary output from longitudinal Ct GAMs (Fig. 2D) by region. Summary from

- 955 longitudinal GAMs fit to variation in population-level Ct across all three regions (Atsinanana, 956 A., Analamanga, B., National, C.) by date.
- 957

958 Table S5. Summary output from individual trajectory GAMs. Summary from individual 959 trajectory GAM used to parameterize within-host viral kinetics model (A.) and individual 960 trajectory GAM used to query the effect of symptom status on Ct variation independent of date 961 of infection onset (B.).

962

963 Table S6. Summary output from population-level symptom status GAM. Summary from 964 population-level GAM used to query the effect of symptom status on Ct variation across all 965 regions, independent of date.

966

967 Table S7. Convergence diagnostics and posterior quantiles for Gaussian process-Ct models.

968 Convergence diagnostics, including \hat{R} , the potential scale reduction factor (values <1.1) and 969 effective population size (values > 200) for all parameters estimated across all three regions via

Gaussian process model fit to Ct time series. Table also includes mean and 95% posterior

- 970
- 971 quantile for each parameter estimate from the fitted model.
- 972

973 Table S8. Convergence diagnostics and posterior quantiles for SEIR-Ct models.

- 974 Convergence diagnostics, including \hat{R} , the potential scale reduction factor (values <1.1) and
- 975 effective population size (values > 200) for all parameters estimated across all three regions at all timepoints via mechanistic SEIR model fit to Ct time series. Table also includes mean and 95% 976
- 977 posterior quantile for each parameter estimate from the fitted model.
- 978